Related Experiment Videos
Iron Pathophysiology in Alzheimer's Diseases
Tao Wang1, Shuang-Feng Xu1, Yong-Gang Fan1
1College of Life and Health Sciences, Northeastern University, No. 195, Chuangxin Road, Hunnan District, Shenyang, 110169, China.
Advances in Experimental Medicine and Biology
|August 29, 2019
Summary
Iron dysregulation in Alzheimer's disease (AD) contributes to neurodegeneration and cognitive decline. Targeting iron metabolism, particularly with iron chelators, shows promise for novel AD therapeutic strategies.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Alzheimer's disease (AD) is characterized by amyloid plaques and neurofibrillary tangles.
- Disordered brain metal ion metabolism, especially iron, is implicated as a risk factor in AD pathogenesis.
- Iron is essential for brain function but its dysregulation can lead to oxidative stress and cellular damage.
Purpose of the Study:
- To investigate the role of iron metabolism in Alzheimer's disease pathogenesis.
- To explore the potential of iron-targeted therapies for AD.
Main Methods:
- Review of evidence linking iron metabolism to AD pathology.
- Analysis of iron deposition in AD patient brains.
- Evaluation of iron chelator efficacy in experimental and clinical settings.
Main Results:
- Abnormal iron metabolism generates reactive oxygen species, causing oxidative stress and damage to cellular components.
- Iron deposition is generally observed in brain regions of AD patients, potentially impairing cognitive function.
- Iron chelators have demonstrated positive outcomes in preclinical studies and some clinical trials.
Conclusions:
- Iron dysregulation is a significant factor in AD development and progression.
- Iron-targeted therapeutic strategies, such as iron chelators, represent a promising new direction for AD treatment.
- Further research focusing on iron homeostasis is crucial for understanding AD etiology and developing prevention strategies.